Resistance to Molecular Therapies for Hepatocellular Carcinoma

1. Auflage 2017
ISBN: 978-3-319-56196-7
Verlag: Springer

Buch, Englisch, 147 Seiten, Format (B × H): 160 mm x 241 mm, Gewicht: 3731 g

Reihe: Resistance to Targeted Anti-Cancer Therapeutics

This volume evaluates the clinical patterns of resistance to sorafenib, the impact of trial design in the second-line setting and the current gold standard to define radiological resistance; describes the molecular mechanisms responsible for treatment resistance in HCC patients, including components of the immune system and tumor microenvironment; determines the role of the cancer stem cell phenotype in resistance; reviews the experimental models to study resistance; and addresses new approaches to overcome resistance to sorafenib, using successful examples from other malignancies.

Zielgruppe

Research

Autoren/Hrsg.

Villanueva, Augusto

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Onkologie, Krebsforschung

Inhaltsverzeichnis

Tumor Heterogeneity and Resistance to Targeted Therapies in Hepatocellular Carcinoma.- Modulating Immune Responses to Overcome Resistance in Hepatocellular Carcinoma.- Role of Tumor Microenvironment in Hepatocellular Carcinoma Resistance.- Contribution of the Cancer Stem Cell Phenotype to Hepatocellular Carcinoma Resistance.- Clinical and Preclinical Perspectives on Mechanisms  of Sorafenib Resistance in Hepatocellular Carcinoma.- Radiological Assessment of Response to Palliative Treatments in Hepatocellular Carcinoma.- Sorafenib and Clinical Patterns of Resistance in hepatocellular carcinoma.- Overcoming Treatment Resistance in Hepatocellular Carcinoma: regorafenib and lessons from other malignancies.

Über Autor(innen)

Augusto Villanueva, MD, PhD, is Assistant Professor, Division of Liver Diseases, Liver Cancer Program, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine, NYC.